NCT07263204 AI-Enabled Diagnosis and Prognosis of Hypertrophic Cardiomyopathy
| NCT ID | NCT07263204 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Condition | Hypertrophic Cardiomyopathy (HCM) |
| Study Type | OBSERVATIONAL |
| Enrollment | 15,000 participants |
| Start Date | 2025-01-01 |
| Primary Completion | 2026-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 15,000 participants in total. It began in 2025-01-01 with a primary completion date of 2026-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
By harnessing artificial intelligence to decode the 12-lead electrocardiogram, the project will enable precise ECG-based phenotyping of hypertrophic cardiomyopathy-accurately classifying septal, apical, and other morphologic subtypes-while simultaneously differentiating HCM from hypertensive heart disease, aortic stenosis, and other phenocopy disorders.
Eligibility Criteria
Inclusion Criteria: 1. Adults aged ≥ 18 years. 2. HCM cohort: Adults diagnosed with hypertrophic cardiomyopathy in accordance with the \*2023 Chinese Guidelines for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy in Adults\*. 3. HCM phenocopy cohort: Adults with an LV wall thickness ≥ 13 mm at any site on echocardiography. 4. Healthy-control cohort: Adults with no history of cardiac disease and no evidence of myocardial hypertrophy on echocardiography. Exclusion Criteria: Patients from whom analyzable ECG data cannot be obtained.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07263204 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hypertrophic Cardiomyopathy (HCM). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07263204 currently recruiting?
Yes, NCT07263204 is actively recruiting participants. Contact the research team at xiexj@zju.edu.cn for enrollment information.
Where is the NCT07263204 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT07263204 clinical trial?
NCT07263204 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. The trial plans to enroll 15,000 participants.